In-Stent Restenosis Clinical Trial
Official title:
PEPCAD DES - Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA Catheter
Verified date | May 2011 |
Source | Klinikum Coburg |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Federal Institute for Drugs and Medical Devices |
Study type | Interventional |
The aim of the study is to assess the efficacy of the Paclitaxel-eluting PTCA - balloon catheter SeQuent® Please to treat in-stent restenoses (ISR) of various drug eluting stents in native coronary arteries with reference diameters between 2.5 mm and ≤ 3.5 mm and lesion lengths ≤ 22 mm. The vessel patency following treatment with SeQuent® Please will be documented in ISR patients that have been treated with the Cypher® or Taxus® drug eluting stent.
Status | Active, not recruiting |
Enrollment | 120 |
Est. completion date | December 2011 |
Est. primary completion date | September 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patient Related - Patients with stable angina pectoris (CCS class 1-3) or with unstable angina pectoris (Braunwald class 1-2, A-C) or documented ischemia or with documented silent ischemia - Patients eligible for coronary revascularization by means of PCI - Patients suitable for coronary revascularization of any sort (balloon angioplasty, device-assisted balloon-angioplasty, or coronary artery bypass grafting) - Patients must be = 18 years of age - Women of childbearing potential may not be pregnant nor have the desire to becoming pregnant during the first year following the study procedure. Hence, patients will be advised to use an adequate birth control method up to and including 6 months follow-up - Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol - Patients must agree to undergo the 6 months angiographic follow-up - Patients must agree to undergo the 1 and 3 year clinical follow-up - Patient is able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of this trial, e.g., balloon angioplasty by means of the paclitaxel-eluting PTCA-balloon catheter or other suitable devices. The patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document. Inclusion Criteria: Lesion Related - In-stent restenosis or Mehran type III stenoses reaching = 2 mm into the adjacent native vessel of a drug eluting stent (DES), in a native coronary artery (reference vessel between = 2.5 and = 3.5 mm, lesion length = 22 mm as angiographically documented) - Diameter stenosis pre procedure must be either = 70 % or = 50 % if ischemia corresponding to the target lesion is documented either by exercise stress ECG, stress echocardiography, scintigraphy, MRT, or suspected based on angina pectoris. - DES in-stent restenosis independent of the the number of metal layers (e.g. restenosed DES following BMS and/or DES implantation(s)) Exclusion Criteria: Patient Related - Patients with acute (< 24 h) or recent (48 hours) myocardial infarction - Patients with unstable angina pectoris (Braunwald class 3) - Patients with severe congestive heart failure - Patients with severe heart failure NYHA IV - Patients demonstrating clinical signs of cardiogenic shock at the time of the procedure (systolic blood pressure of less than 80 mmHg requiring inotropic support, IABP and/or fluid challenge) - Patients with severe valvular heart disease - Women who are pregnant or lactating patients with life expectancy of less than five years or factors making clinical follow-up difficult - Patients with another coronary stent previously implanted into the target vessel - Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication is contraindicated - Patients who had a cerebral stroke < 6 months prior to the procedure - Patient participates in other clinical trials involving any investigational device or drug - Untreated hyperthyroidism - Patient has presence or history of severe renal failure (GFR < 30ml/min) and is therefore not eligible for angiography. Patient's serum creatinine levels must be documented. - Post transplantation of any organ or immune suppressive medication - Other disease to jeopardize follow-up (e.g. malignoma) - Addiction to any drug or to alcohol - Patients with any type of surgery during the week preceding the interventional procedure - Conditions which prevent the intake of the double anti-platelet therapy for three months Exclusion Criteria: Lesion Related - Evidence of extensive thrombosis within target vessel before the intervention - Side branch > 2 mm in diameter originating from the stent - Bifurcate lesion - Left main coronary artery stenosis - Multilesion percutaneous coronary intervention within the same artery (a main artery e.g., LCX and its side branch e.g. OMS are considered as different arteries) - Percutaneous coronary intervention of venous graft - Coronary artery occlusions of any type (e.g. acute or chronic) - In-segment stenosis of the native vessel within the 5 mm adjacent to the stent - Lesion within 1 mm of vessel origin Exclusion Criteria: Related to Concomitant Medication - Patient is intolerant to aspirin and/or the ADP-antagonists clopidogrel or has a history of neutropenia, thrombocytopenia induced by ADP-antagonists, or severe hepatic dysfunction prohibiting the use of clopidogrel - Patient has leucopoenia (leukocyte count < 109/liter for more than 3 days) - Patient has neutropenia (ANC < 1000 neutrophils/mm3 for more than 3 days) - Patient has a history of peptic ulcer or gastric/intestinal bleeding during the past 6 months - Patient has a history of thrombocytopenia (< 100,000 platelets/mm3) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Zentralklinik Bad Berka GmbH | Bad Berka | |
Germany | Klinikum Bayreuth | Bayreuth | |
Germany | Klinikum Coburg | Coburg | |
Germany | Klinikum Kulmbach | Kulmbach | |
Germany | Herzzentrum Leipzig | Leipzig | |
Germany | Universitätsklinikum Schleswig-Holstein, Campus Lübeck | Lübeck | |
Germany | LMU - Klinikum der Universität München | Munich | |
Germany | Klinikum Weiden | Weiden |
Lead Sponsor | Collaborator |
---|---|
Klinikum Coburg |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Late lumen loss | 6 months | No | |
Secondary | Occurrence of acute (up to 48 hours), subacute (up to 30 days), and late thrombosis | 3 years | Yes | |
Secondary | Major adverse cardiac event (MACE) rate | 30 days | Yes | |
Secondary | Percent in-stent stenosis | 6 months | No | |
Secondary | Percent in-segment stenosis | 6 months | No | |
Secondary | In-stent late loss index | 6 months | No | |
Secondary | Angiographic binary in-stent stenosis rate | 6 months | No | |
Secondary | In-segment late loss index | 6 months | No | |
Secondary | Angiographic binary in-segment stenosis rate | 6 months | No | |
Secondary | Indication for premature follow-up | 6 months | No | |
Secondary | Type of recurrence (Mehran-Classification) | 6 months | No | |
Secondary | Target vessel failure | 6 months | No | |
Secondary | MACE Rate | 6 months | Yes | |
Secondary | MACE Rate | 1 year | Yes | |
Secondary | MACE Rate | 3 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00341562 -
Genomics of In-Stent Restenosis
|
N/A | |
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Not yet recruiting |
NCT06090890 -
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
|
Phase 4 | |
Active, not recruiting |
NCT05731700 -
CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
|
N/A | |
Completed |
NCT03260517 -
The PREVAIL Study
|
N/A | |
Not yet recruiting |
NCT03588962 -
Metal Allergy In-Stent Restenosis Study
|
N/A | |
Completed |
NCT00393315 -
P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses
|
Phase 2 | |
Recruiting |
NCT03874481 -
The Effect of Sleep Quality on Coronary Artery Disease and In Stent Restenosis
|
||
Active, not recruiting |
NCT01127958 -
DARE-trial: A Trial Studying the Effect of the SeQuent Please Drug-eluting Balloon Compared to the Xience Prime Drug-eluting Stent for the Treatment of Stenosis of an Earlier Implanted Stent.
|
N/A | |
Active, not recruiting |
NCT04647253 -
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)
|
Phase 3 | |
Active, not recruiting |
NCT03529006 -
Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis
|
N/A | |
Completed |
NCT00485030 -
Diffuse Type In-Stent Restenosis After Drug-Eluting Stent
|
Phase 4 | |
Not yet recruiting |
NCT03809754 -
Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis
|
N/A | |
Completed |
NCT00916279 -
PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT05473884 -
Lesion Preparation in Femoropopliteal Artery Occlusion Disease
|
||
Recruiting |
NCT01239940 -
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)
|
Phase 4 | |
Active, not recruiting |
NCT01239953 -
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)
|
Phase 4 | |
Not yet recruiting |
NCT06148441 -
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention
|
||
Completed |
NCT05512832 -
In-stent Restenosis and Pericoronary Fat Attenuation Index
|
||
Recruiting |
NCT03521843 -
LDD in Treatment of Femoropopliteal ISR
|
N/A |